AI summary · may contain errors
Pegcetacoplan sustained proteinuria reduction through 52 weeks in VALIANT participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, maintaining about a 67% decrease.
- Open access
